# Internal Review (Claude Code) — Round 1

## PART 1: CRITICAL REVIEW

### 1. Identification and Empirical Design

The paper exploits Flood Re's 2016 launch as a quasi-experiment. The core DiD compares High/Medium flood-risk postcodes to Lower/No-risk postcodes. The identification is creative but faces a serious pre-trends problem that the author commendably acknowledges.

**Strengths:**
- The dose-response specification is the strongest identification element — the monotone gradient (only High-risk significant) is hard to explain without the insurance channel.
- The institutional setting is well-described, with clear policy dates and eligibility rules.
- The universe of Land Registry transactions provides exceptional statistical power.

**Weaknesses:**
- **Pre-trends violation (p. 13):** Event-study coefficients are positive and significant in the pre-period (0.030–0.038). This is the paper's central identification challenge. The author's defense — that coefficients are "flat rather than trending" — is somewhat tenuous. A level shift in pre-treatment coefficients still indicates a confound.
- **Triple-diff is imprecise:** The DDD estimate (-0.020, SE=0.011) fails to reach significance, undermining the eligibility-based identification. The measurement error explanation is plausible but unverifiable.
- **Anticipation:** The Water Act 2014 announcement creates a two-year anticipation window that contaminates the pre-period and makes the choice of base year (2015) problematic.

### 2. Inference and Statistical Validity

- Standard errors are clustered at the local authority level (363 clusters) — appropriate.
- Sample sizes are reported consistently across specifications.
- The N difference between Columns 1 and 2/3 (12,415,343 vs 12,415,220) is due to singleton removal by fixest — correctly documented.

### 3. Robustness and Alternative Explanations

- Placebo tests at 2012 and 2014 yield positive significant coefficients (2.1% and 1.6%), which the author honestly reports as reinforcing the pre-trend concern rather than spinning as "placebo passes."
- Excluding London doesn't change results — good.
- The dose-response pattern is the most convincing robustness check.
- Missing: no Callaway-Sant'Anna or other heterogeneity-robust DiD estimator.

### 4. Contribution and Literature Positioning

The paper positions itself well relative to three literatures. The distinction between insurance-market-failure and actuarial risk pricing is genuinely novel.

**Missing citations to consider:**
- Kousky and Michel-Kerjan (2017) on NFIP pricing
- Harrison et al. (2020) on UK flood insurance market
- Lamond and Proverbs (2006) on flood risk and UK property values (direct UK predecessor)

### 5. Results Interpretation and Claim Calibration

- The welfare calculation (£2–3 billion) is presented with appropriate caveats.
- The regional heterogeneity is interesting but the North East outlier (12.6%) deserves more scrutiny — only 8,430 flood-risk transactions in a region with severe historical flooding may confound.
- The conclusion appropriately notes limitations.

## PART 2: CONSTRUCTIVE SUGGESTIONS

### Must-Fix Issues
1. **Address pre-trends more formally.** Consider de-trending or presenting bounds on the treatment effect under different assumptions about linear pre-trends.
2. **Discuss the placebo failure implications.** The 2012 and 2014 placebos "passing" with significant positive coefficients is actually a failure — this should be framed more carefully.

### High-Value Improvements
1. **Callaway-Sant'Anna estimator** as robustness — even though this is a single-treatment-date design, it would demonstrate robustness to heterogeneous treatment effects.
2. **Synthetic control for regions** — particularly useful for the North East, where the effect is large and the sample small.
3. **Bandwidth sensitivity** — show results restricting to narrower time windows around 2016.

### Optional Polish
1. Consider adding a map of flood risk intensity by local authority.
2. The volume analysis is descriptive and somewhat disconnected — either develop it more formally or trim it.

## 7. OVERALL ASSESSMENT

**Key strengths:** Novel question, excellent data coverage (universe of transactions), honest about limitations, compelling dose-response pattern.

**Critical weaknesses:** Pre-trends violation undermines the main DiD; triple-diff imprecise; placebo tests fail.

**Publishability:** The dose-response specification salvages the paper's core contribution. With more formal treatment of the pre-trends issue and appropriate caveats, this could be a solid AEJ:Policy contribution.

DECISION: MAJOR REVISION
